

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2011; month=12; day=17; hr=14; min=50; sec=21; ms=300;
]

=====

Application No: 10585277 Version No: 2.0

Input Set:

Output Set:

Started: 2011-12-09 11:45:10.307
Finished: 2011-12-09 11:45:10.887
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 580 ms
Total Warnings: 4
Total Errors: 2
No. of SeqIDs Defined: 4
Actual SeqID Count: 4

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)

SEQUENCE LISTING

<110> William Marsh Rice University

<120> Fullerene-Based Amino Acids

<130> 11321-P080WOUS

<140> 10585277

<141> 2011-12-09

<150> PCT/US05/001187

<151> 2005-01-14

<150> US 60/536,544

<151> 2004-01-14

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<220>

<221> Xaa

<222> (7)..(7)

<223> Xaa is bulky amino acid (BAA)

<400> 1

Glu Ile Ala Gln Ser Glu Xaa Glu Leu Gln Ala Ile Glu

1

5

10

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<220>

<221> Xaa

<222> (1)..(1)

<223> Xaa is bulky amino acid (BAA)

<400> 2

Xaa Glu Glu Glu Glu Gly Gly Gly Ser
1 5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 3

Glu Ile Ala Gln Leu Glu
1 5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 4

Glu Ile Ser Gln Leu Glu Gln
1 5